A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1

This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to standard-dose treatment, in treatment-naive participants with CHC, genotype 1 infection.

Study Overview

• Status: Completed
• Conditions: Hepatitis C, Chronic
• Intervention / Treatment: Drug: PEG-IFN alfa-2a; Drug: Ribavirin

• Study Type: Interventional
• Enrollment (Actual): 896
• Phase: Phase 4

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, 1640
  • Buenos Aires, Argentina, C1282AFE
  • La Plata, Argentina, B1902AVF
  • Rosario, Argentina, 2000
• Australia
  • Adelaide, Australia, 5000
  • Adelaide, Australia, 5042
  • Bankstown, Australia, 2200
  • Box Hill, Australia, 3128
  • Brisbane, Australia, 4029
  • Cottontree, Australia, 4558
  • Darlinghurst, Australia, 2010
  • Douglas, Australia
  • Fitzroy, Australia, 3065
  • Fremantle, Australia, 6160
  • Geelong, Australia, 3220
  • Greenslopes, Australia, 4120
  • Kingswood, Australia
  • Lismore, Australia, 2480
  • Liverpool, Australia, 1871
  • Liverpool, Australia, 2170
  • Melbourne, Australia, 3181
  • Melbourne, Australia, 3084
  • Melbourne, Australia, 3011
  • Melbourne, Australia, 3186
  • Miranda, Australia, 2228
  • Nedlands, Australia, 6009
  • New Lambton Heights, Australia, 2310
  • Parkville, Australia, 3052
  • Perth, Australia, 6001
  • Sydney, Australia, 2050
  • Sydney, Australia, 2145
  • Sydney, Australia, 2139
  • Sydney, Australia, 2010
  • Victoria, Australia, 3199
  • Woden, Australia, 2606
  • Wollongong, Australia, 2500
  • Woolloongabba, Australia, 4102
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 4N1
    • Edmonton, Alberta, Canada, T5H 4B9
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 1M9
  • Ontario
    • Mississauga, Ontario, Canada, L5M 2V8
  • Quebec
    • Montreal, Quebec, Canada, H3T 1E2
• Mexico
  • Guadalajara, Mexico, 44650
  • Guadalajara, Mexico, 44280
  • Monterrey, Mexico, 64460
• New Zealand
  • Auckland, New Zealand, 100
  • Hamilton, New Zealand
  • Riccarton, Christchurch, New Zealand, 8011
• Thailand
  • Bangkok, Thailand, 10400
  • Bangkok, Thailand, 10700
  • Chiang Mai, Thailand, 50202

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of chronic CHC, genotype 1
• Chronic liver disease consistent with CHC on a biopsy sample obtained within the previous 36 months as judged by a local pathologist (all countries except Australia)
• Infection with Hepatitis C virus (Australian sites only had to meet Section 100 criteria for treatment with PEG-IFN alfa-2a plus ribavirin)
• Compensated liver disease
• Naive to interferon-based therapy for CHC infection

Exclusion Criteria:

• Systemic antiviral, antineoplastic, or immunomodulatory treatment within 6 months of study drug
• Coinfection with active hepatitis A or B virus, or with human immunodeficiency virus (HIV)
• Chronic liver disease other than CHC infection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PEG-IFN alfa-2a+Ribavirin - Induction Treatment; Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.	Drug: PEG-IFN alfa-2a; PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.; Other Names: Pegasys; Drug: Ribavirin; Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.; Other Names: Copegus
Experimental: PEG-IFN alfa-2a+Ribavirin - Standard Treatment; Participants will receive 48 weeks of standard therapy with PEG-IFN alfa-2a, 180 mcg SC once weekly, along with ribavirin, 1000 or 1200 mg orally daily in divided doses.	Drug: PEG-IFN alfa-2a; PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.; Other Names: Pegasys; Drug: Ribavirin; Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.; Other Names: Copegus

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Sustained Virological Response According to Scheduled Treatment Period	Sustained virological response was calculated as the percentage of participants with undetectable (less than [<] 15 international units per milliliter [IU/mL]) hepatitis C virus (HCV) ribonucleic acid (RNA) as measured by the Roche TaqMan HCV Test 24 weeks after completion of the scheduled 48-week treatment period.	Week 72

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With End-of-Treatment Virological Response According to Scheduled Treatment Period	Virological response at the end of the scheduled treatment period was defined as the percentage of participants with undetectable (<15 IU/mL) HCV RNA as measured by the Roche TaqMan HCV Test at Week 48.	Weeks 48
Percentage of Participants With Virological Responses Over Time	Virological response was defined as undetectable HCV RNA (<15 IU/mL) as measured by the Roche TaqMan HCV Test. Participants without HCV RNA measurements at a study week are considered non responders at that study week.	Weeks 4, 8, 12, and 24
Percentage of Participants With Relapse of End-of-treatment Virological Response	Relapse was determined based on virological response at the actual end of treatment and was calculated by dividing the number of participants who achieved a virological response at end of treatment but later had detectable HCV RNA at the last assessment post-treatment by the number of participants with a virological response at end of treatment, defined as undetectable HCV RNA (<15 IU/mL). Participants who achieved a virological response at end of treatment but did not have any HCV RNA assessment during follow-up were excluded and were not considered as having relapsed. However, if no assessment was available within the end of-treatment time window but the participant had a sustained virological response according to the actual treatment period, backward imputation was used and the participant was considered to have achieved an end-of-treatment virological response in the analysis.	Actual end of treatment (Week 48) up to last follow up (maximum up to Week 72)
Percentage of Participants With Predictive Values of Virological Response for Sustained Virological Response	The ability of virological responses to predict sustained virological response according to the scheduled treatment periods was assessed in terms of positive predictive value (PPV) and negative predictive value (NPV). The PPV indicates probability of achievement of viral suppression (undetectable HCV RNA) for achieving a sustained virological response and the NPV indicates probability of not achieving viral suppression for not achieving a sustained virological response. The PPV at Week 4 or 12 was calculated as the number of participants who achieved viral suppression both at Week 4 or 12 and at Week 72 divided by the number of participants who achieved viral suppression at Week 4 or 12, multiplied by 100. The NPV at Week 4 or 12 was calculated as the number of participants who failed to achieve viral suppression at Week 4 or 12 and at Week 72 divided by the number of participants who failed to achieve viral suppression at Week 4 or 12, multiplied by 100.	Weeks 4, 12, and 72
Change From Baseline in Log10 HCV RNA Values	The mean decrease in log10 HCV RNA levels from baseline was assessed in both the induction group and the standard group.	Baseline, Weeks 4, 8, 12, 24, and at end of treatment (EoT) (maximum up to Week 48)

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: August 1, 2004
• Primary Completion (Actual): March 1, 2009
• Study Completion (Actual): March 1, 2009

Study Registration Dates

• First Submitted: September 13, 2005
• First Submitted That Met QC Criteria: September 13, 2005
• First Posted (Estimate): September 19, 2005

Study Record Updates

• Last Update Posted (Estimate): August 4, 2016
• Last Update Submitted That Met QC Criteria: June 23, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis; Hepatitis A; Hepatitis C; Hepatitis C, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites; Antineoplastic Agents; Ribavirin; Peginterferon alfa-2a; Interferon alpha-2
• Other Study ID Numbers: ML17908